Attached files
file | filename |
---|---|
EX-99 - PRESS RELEASE - VistaGen Therapeutics, Inc. | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF
1934
Date
of Report (Date of earliest event reported): February 20, 2020
VistaGen Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
NEVADA
|
000-54014
|
20-5093315
|
(State or other jurisdiction of
incorporation)
|
(Commission File Number)
|
(IRS Employer Identification
Number)
|
343 Allerton Ave.
South San Francisco, California
94090
|
(Address of principal executive
offices)
|
(650)
577-3600
(Registrant’s telephone number, including area
code)
Not Applicable
(Former name or former address, if changed since last
report)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the
following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a -12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d -2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e -4(c))
Securities
registered pursuant to Section 12(b) of the
Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par
value $0.001 per share
|
VTGN
|
Nasdaq Capital
Market
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (17 CFR
230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17
CFR 240.12b-2)
Emerging Growth Company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the
Exchange Act ☐
Item
8.01. Other Events.
On
February 20, 2020, VistaGen Therapeutics, Inc. (the
“Company”)
announced positive results from a newly published exploratory Phase
2a clinical study of PH10, the Company’s investigational
first-in-class, rapid-onset synthetic neurosteroid nasal spray, for
treatment of major depressive disorder. Results of the
double-blind, randomized, placebo-controlled Phase 2a study have
been published in the peer-reviewed British Journal of
Pharmaceutical and Medical Research. A copy of the press
release is attached to this Current Report on Form 8-K as Exhibit
99.1.
Item 9.01. Exhibits.
(d)
Exhibits
Exhibit Number
|
|
Description
|
|
Press Release issued
by VistaGen Therapeutics, Inc., dated February 20,
2020.
|
|
|
|
|
Signatures
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
VistaGen Therapeutics,
Inc.
|
|
|
|
|
Date: February 20,
2020
|
By:
|
/s/
Shawn K.
Singh
|
|
|
Shawn K.
Singh
Chief Executive
Officer
|